Distinguished in Gastrointestinal Stromal Tumor

David P. Goldstein

320-346 Barker St, 
Randwick, NSW, AU 
Distinguished in Gastrointestinal Stromal Tumor
320-346 Barker St, 
Randwick, NSW, AU 
OverviewLocationsClinical Research

Overview

David Goldstein practices in Randwick, Australia. Mr. Goldstein is rated as a Distinguished expert by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Peripheral Neuropathy, Pancreatic Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Thyroidectomy, and Laryngectomy.

His clinical research consists of co-authoring 649 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Gastrointestinal Stromal Tumor.

Gender
Male

Locations

320-346 Barker St, Randwick, NSW 2031, Australia
Other Locations
High Street, Kensington, NSW 2032, Australia
Barker Street, Sydney, NSW 2031, Australia
119-143 Missenden Rd, Camperdown, NSW 2050, Australia
Barker Street, Randwick, NSW 2031, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?
Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer
Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Study Phase: Phase 3
View 2 Less Clinical Trials

649 Total Publications

Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changes.
Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changes.
Journal: Clinical & experimental optometry
Published: January 22, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Goldstein's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 12 Advanced Conditions
View All 67 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile